European Commission approves EUR Neffy (epinephrine nasal spray) for emergency treatment of severe allergic reactions in adults and children
ARS Pharmaceuticals, Inc. announced the European Commission's approval of EURneffy for emergency treatment of severe allergic reactions in adults and children weighing at least 30 kilograms
This approval introduces the first needle-free adrenaline delivery method in the European Union (EU) in over 30 years. EURneffy, known as neffy in the United States, is a nasal spray formulation of adrenaline, which is the primary treatment for anaphylaxis, a severe and potentially life-threatening allergic reaction. The product's design aims to address the underutilization of adrenaline due to the limitations of current injectable therapies.
Professor Antonella Muraro, lead author of the European Academy of Allergology and Clinical Immunology (EAACI) treatment guidelines for anaphylaxis, highlighted the significance of a needle-free option that may encourage more patients to carry and use adrenaline promptly during emergencies.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins